High-Risk Needlestick in a Pregnant Nurse With a Reactive Source
A 29-year-old RN at 26 weeks' gestation sustains a deep needlestick with a 22-gauge hollow-bore needle while drawing blood from a 57-year-old man admitted with alcohol-related pancreatitis and fluctuating mental status. She recapped the needle before the injury. The chart documents no HIV, HBV, or HCV history; the patient is confused and cannot consent to testing, and no next of kin can be reached. The nurse's employee health file shows a completed hepatitis B series with anti-HBs of 220 mIU/mL four years ago and no hepatitis C testing. She has had no prior needlestick and takes only prenatal vitamins. Hospital policy permits source testing without consent when the source cannot consent, consistent with state law. On day 2, the source's HIV antigen/antibody screen is reactive and he is HBsAg positive. The nurse asks Employee Health whether she should "wait for the confirmatory test before starting anything."
1. What is your answer about waiting, and what HIV post-exposure prophylaxis would you start? Address the pregnancy specifically.
Read the worked answer
Do not wait. HIV PEP should begin as soon as possible after exposure, ideally within hours and no later than 72 hours; the benefit falls sharply with delay. A reactive fourth-generation antigen/antibody screen in a patient with this risk profile makes HIV infection highly likely, and the confirmatory result will not change the decision to start now. PEP can be stopped if the source is ultimately confirmed negative.
Regimen: a three-drug, 28-day course - tenofovir disoproxil fumarate/emtricitabine once daily plus dolutegravir 50 mg daily (raltegravir 400 mg twice daily is an alternative). Both dolutegravir and raltegravir are considered acceptable in pregnancy and dolutegravir is currently a preferred agent; the earlier neural tube concern derived from periconception exposure, not third-trimester initiation. Consult the National Clinician Consultation Center PEPline and coordinate with her obstetrician the same day.
Practical points that get missed:
- Baseline labs for the worker: HIV antigen/antibody, CBC, creatinine, hepatic panel, and hepatitis serologies.
- Drug interactions: prenatal vitamins, iron, calcium, and antacids chelate dolutegravir - she must separate dosing by at least two hours before or six hours after.
- Address nausea and adherence explicitly; a pregnant nurse with GI side effects is at high risk of abandoning the course.
- Follow-up HIV testing at baseline, 6 weeks, 12 weeks, and 4–6 months.
- Document the conversation: a decision not to offer PEP must be justified as thoroughly as a decision to start it.
2. How do you manage the hepatitis B and hepatitis C components of this exposure?
Read the worked answer
Hepatitis B - she is already protected. A documented anti-HBs of 220 mIU/mL after a completed series is a confirmed vaccine response (≥10 mIU/mL is protective). No HBIG and no vaccine booster are indicated, even though the source is HBsAg positive. Repeat anti-HBs if there is any doubt about the record's provenance, but do not give HBIG reflexively - it is expensive, scarce, and unnecessary in a documented responder. If she had been a non-responder, the answer would be HBIG plus revaccination.
Hepatitis C - no prophylaxis exists, so the plan is detection. Obtain baseline HCV antibody with reflex to RNA. If negative, repeat HCV RNA at 4–6 weeks or HCV antibody at 4–6 months; either strategy is acceptable, and RNA detects infection earlier. If she seroconverts or RNA is positive, refer for direct-acting antiviral therapy, which achieves sustained virologic response in more than 95% of cases. Defer treatment until after delivery unless a specialist manages it; cure before or after pregnancy prevents chronic liver disease.
Counseling: explain the differing time courses - hepatitis B is settled (immune), hepatitis C is a monitoring question, and HIV is the time-critical one. Give her written instructions on symptoms to report and a single point of contact. Do not let the HIV discussion crowd out the fact that her hepatitis B immunity is intact.
3. What documentation, regulatory obligations, and program-level corrective actions follow from this injury?
Read the worked answer
Individual documentation: exposure report with time, device, body fluid, route, and infectious status; the source testing process and legal basis; the PEP regimen, start time, and follow-up schedule; and confidential storage of the medical record separate from the personnel file.
Regulatory: the injury is presumptively recordable on the OSHA 300 log because HIV PEP constitutes medical treatment beyond first aid, and it belongs in the sharps injury log with device type. Confirm state requirements for source testing without consent and for notifying the source patient afterward if he recovers capacity. Retain records per the bloodborne pathogens standard.
Program-level root cause: a 22-gauge hollow-bore needle was recapped by hand. Ask three questions:
- Was a safety-engineered device available on the unit, and if so why was it not used?
- Was the patient's fluctuating mental status an anticipated risk that warranted a second staff member or a different device?
- Do staff know where safety devices are stocked on nights and weekends?
Metrics and communication: track needlestick rates per 100 full-time-equivalent employees, recapping-related injuries as a proportion of total sharps injuries, and PEP initiation within two hours. Feed the case - de-identified - to unit education. Also review sick leave and staffing policy: staff who fear reporting or fear the cost of time off will not present promptly, which converts a treatable exposure into a preventable seroconversion.